跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Qilu Pharmaceutical (Hainan) Co., Ltd.

首页临床试验发起方与机构Qilu Pharmaceutical (Hainan) Co., Ltd.

Qilu Pharmaceutical (Hainan) Co., Ltd.

Room A, No.273, Nanhai Boulevard, State Hi-and-New Tech Park, Haikou, Hainan, 中国

别名:

qilu pharmaceutical co., (hainan) ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

15

11 进行中

药物批准

10

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

3 期

5

33.3%

1 期

2

13.3%

Unknown

2

13.3%

4 期

1

6.7%

试验状态分布

已完成

2

13.3%

尚未招募

11

73.3%

招募中

2

13.3%

相关临床试验

该机构主办的试验（15）

QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration

Sep 202642 名受试者

A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)

Sep 202550 名受试者

Bioequivalence study of Olaparib Tablets 150 mg (2x150 mg tablets) with Lynparza® 150 mg Film-coated tablets (Olaparib (2x150 mg tablets)) in adult patients with carcinoma of the ovary, breast, prostate or adenocarcinoma of the pancreas under fasting condition.

Aug 202540 名受试者

Bioequivalence study of Olaparib Tablets 150 mg (2x150 mg tablets) with Lynparza® 150 mg Film-coated tablets (Olaparib (2x150 mg tablets)) in adult patients with carcinoma of the ovary, breast, prostate or adenocarcinoma of the pancreas under fed condition.

Aug 202540 名受试者

A Study of QLM2011 in Subjects With Advanced Solid Tumors

May 2025172 名受试者

This is a study of Doxorubicin Pegylated Liposomal 2 mg/mL Concentrate for Solution for Infusion in Patients with Advanced Ovarian Cancer or Metastatic Breast Cancer

Jan 202568 名受试者

Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Jun 2024194 名受试者

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Feb 2024518 名受试者

第 1 页，共 2 页

药物批准

按机构分类的批准

PHILIPPINES

Philippines FDA

2

药物批准

NPRA

National Pharmaceutical Regulatory Agency

8

药物批准

近期批准

Qilu Palonosetron Hydrochloride Injection 0.25mg/5ml

Oliptin 5mg/ml Concentrate for Solution for Infusion

hovid Oxaliplatin 100mg Powder for Concentrate for Solution for Infusion

Hovid Gefitinib Tablets 250mg

hovid Oxaliplatin 50mg Powder for Concentrate for Solution for Infusion

Qilu DECITABINE LYOPHILISED POWDER FOR INFUSION 50 MG/VIAL

Inotecam 20mg/ml Concentrate for Solution for Infusion

hovid Irinotecan hydrochloride 20 mg/ ml concentrate for solution for infusion

30 January 2025

资讯

暂无资讯文章

本页目录

概览
相关临床试验15
药物批准10
资讯

返回机构列表